Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Callen

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Cell Cycle (Georgetown, Tex.)|January 5, 2013
p53 continues to surprise: high levels of p53 can suppress apoptosisDavid F Callen
Journal of the National Cancer Institute|August 21, 2003
Absence of the Epstein-Barr virus genome in breast cancer-derived cell linesPeter Speck, David F Callen, Richard Longnecker
Oncotarget|April 22, 2017
MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4Qingqing Wang, Luke A Selth, David F Callen
The Journal of Steroid Biochemistry and Molecular Biology|February 14, 2018
Vitamin D<sub>3</sub> signaling and breast cancer: Insights from transgenic mouse modelsLei Sheng, David F Callen, Andrew G Turner
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The oncogenic role of miR-155 in breast cancerSam Mattiske, Rachel J Suetani, Paul M Neilsen, et al.
Biomacromolecules|December 30, 2009
Mechanistic insight into cell growth, internalization, and cytotoxicity of PAMAM dendrimersSrinivas Parimi, Timothy J Barnes, David F Callen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 6, 2011
The application of delivery systems for DNA methyltransferase inhibitorsSue Ping Lim, Paul Neilsen, Raman Kumar, et al.
Sarcoma|January 4, 2011
Targeting the p53 Pathway in Ewing SarcomaPaul M Neilsen, Kathleen I Pishas, David F Callen, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S ProteasomeXiaozhou Zhang, Alaknanda Adwal, Andrew G Turner, et al.
Bioorganic & Medicinal Chemistry|June 24, 2017
Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicityBeatriz Blanco, Kathryn A Palasis, Alaknanda Adwal, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Cell Cycle (Georgetown, Tex.)|January 5, 2013
p53 continues to surprise: high levels of p53 can suppress apoptosisDavid F Callen
Journal of the National Cancer Institute|August 21, 2003
Absence of the Epstein-Barr virus genome in breast cancer-derived cell linesPeter Speck, David F Callen, Richard Longnecker
Oncotarget|April 22, 2017
MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4Qingqing Wang, Luke A Selth, David F Callen
The Journal of Steroid Biochemistry and Molecular Biology|February 14, 2018
Vitamin D<sub>3</sub> signaling and breast cancer: Insights from transgenic mouse modelsLei Sheng, David F Callen, Andrew G Turner
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The oncogenic role of miR-155 in breast cancerSam Mattiske, Rachel J Suetani, Paul M Neilsen, et al.
Biomacromolecules|December 30, 2009
Mechanistic insight into cell growth, internalization, and cytotoxicity of PAMAM dendrimersSrinivas Parimi, Timothy J Barnes, David F Callen, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 6, 2011
The application of delivery systems for DNA methyltransferase inhibitorsSue Ping Lim, Paul Neilsen, Raman Kumar, et al.
Sarcoma|January 4, 2011
Targeting the p53 Pathway in Ewing SarcomaPaul M Neilsen, Kathleen I Pishas, David F Callen, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S ProteasomeXiaozhou Zhang, Alaknanda Adwal, Andrew G Turner, et al.
Bioorganic & Medicinal Chemistry|June 24, 2017
Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicityBeatriz Blanco, Kathryn A Palasis, Alaknanda Adwal, et al.
Pageof 6